Market Overview

Aegis Capital Reiterates Buy Rating on BioSpecifics Technologies Ahead of Conference Call


In a report published Monday, Aegis Capital reiterated its Buy rating and $50.00 price target on BioSpecifics Technologies Corp. (NASDAQ: BSTC).

Aegis Capital noted, “We are revising our numbers ahead of BioSpecifics' earnings conference call this week to account for the fact that, unlike its partner Auxilium Pharmaceuticals, BioSpecifics is not recognizing additional revenue in 4Q 2012 as a result of Pfizer's termination of its licensing agreement with Auxilium on Xiaflex in Europe. Regardless, we continue to believe that investors should take note of BioSpecifics' low valuation and risk-mitigated status at this juncture. From our perspective, the firm could have a catalyst-rich 2013. In particular, we expect proof-of-concept data in human and canine lipoma clinical trials with Xiaflex in the summer.”

BioSpecifics Technologies Corp. closed on Friday at $16.29.

Latest Ratings for BSTC

Oct 2020HC Wainwright & Co.DowngradesBuyNeutral
Jul 2020HC Wainwright & Co.MaintainsBuy
Nov 2017H.C. WainwrightMaintainsBuy

View More Analyst Ratings for BSTC
View the Latest Analyst Ratings


Related Articles (BSTC)

View Comments and Join the Discussion!

Posted-In: Aegis CapitalAnalyst Color Reiteration Analyst Ratings

Latest Ratings

TXNDeutsche BankMaintains170.0
BYDDeutsche BankMaintains56.0
MELIDeutsche BankMaintains2,200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at